Application of mbl in the preparation of drugs for preventing or treating effector T-cell-induced diseases
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A cell and drug technology, applied to metabolic diseases, antibacterial drugs, drug combinations, etc., to achieve the effect of rich sources and strong regenerative ability
Active Publication Date: 2020-03-17
XINXIANG MEDICAL UNIV
View PDF3 Cites 0 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
However, whether there are still unknown factors that promote the inhibitory effect of Treg cells needs to be further developed and studied urgently
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0031] Experimental Materials
[0032] 1. The source of cells used in the experiment
[0033] Neonatal umbilical cord blood was collected from the Third Affiliated Hospital of Xinxiang Medical College and the Department of Obstetrics and Gynecology of Xinxiang First People's Hospital of full-term healthy newborns. Immediately after the fetus was delivered, blood was collected from the umbilical vein of the placenta and placed in a blood collection bag containing 28 mL of preservation solution. All blood samples were delivered to the laboratory within 4 hours after sampling.
[0034] 2. Main reagents
[0035] Medium RPMI1640, fetal bovine serum (FBS), and 10×PBS solution were all purchased from Thermo Fisher Scientific.
[0036] Lymphocyte separation medium (Ficoll-Paque PLUS), which is a sterile endotoxin (<0.12EU / mL) test solution of FicollTMPM400 and sodium diatrizoate with a density of 1.077g / mL, was purchased from GE Healthcare Life Sciences.
[0037] Anti-human CD3 mon...
Embodiment 2
[0094] Experimental Materials
[0095] 1. The source of cells used in the experiment
[0096] Reference example 1
[0097] 2. Main reagents
[0098] Reference example 1
[0099] 3. Main instruments and equipment
[0100] Reference example 1
[0101] 4. Preparation of common reagents
[0102] Reference example 1
[0103] experimental method
[0104] 1. Preparation of umbilical cord blood mononuclear cells
[0105] Reference example 1
[0106] 2. Coated with anti-CD3mAb
[0107] Reference example 1
[0108] 3. Magnetic separation of CD4+CD25-T cells and CD4+CD25+T cells
[0109] sample preparation
[0110] Peripheral mononuclear cells were separated by density gradient centrifugation. To remove platelets, cells were resuspended in buffer and centrifuged at 200×g for 10-15 min. The supernatant was carefully aspirated and washed repeatedly.
[0111] Magnetic labeling of non-CD4+ T cells
[0112] The whole process should be completed quickly, and the cells should be k...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Property
Measurement
Unit
concentration
aaaaa
aaaaa
Login to view more
Abstract
The invention discloses the application of MBL in the preparation of drugs for preventing or treating effector T cell-induced diseases, and belongs to the technical field of new applications of mannan-binding lectins. The gist of the technical solution of the present invention is: the application of MBL in the preparation of drugs for the prevention or treatment of infectious diseases, autoimmune diseases or / and allergic diseases caused by effector T cells, wherein MBL inhibits the proliferation of effector T cells by enhancing iTreg cells achieve the efficacy of the drug. The present invention obtains the new factor that regulates Tregs cell inhibitory function through research, namely MBL directly strengthens Tregs cell to effector T cell proliferation inhibitory effect; The present invention highlights a kind of new function of MBL, not only plays an important anti-inflammatory role in innate immunity Infection, and in the intervention of Tregs cell function, it may be a target for the treatment of various autoimmune and inflammatory diseases.
Description
technical field [0001] The invention relates to the technical field of new applications of mannan-binding lectins, in particular to the application of MBL in the preparation of drugs for preventing or treating diseases induced by effector T cells. Background technique [0002] Mannose-binding lectin (mannan-binding lectin, MBL) is a highly conserved plasma protein mainly secreted by hepatocytes, and it is a member of the collectins family in the C-type lectin superfamily. MBL is also an acute phase response protein, and its plasma concentration can increase 2-3 times during stress (such as pathogen infection, surgery, etc.). MBL, known as ante-antibody, widely recognizes sugar structures distributed on the surface of various pathogens such as bacteria, viruses, parasites, fungi, etc., including D-mannose, through its carbohydrate recognition domain (CRD) Sugar, L-fucose, N-acetylglucosamine, N-acetylmannosamine, etc. Its collagen-like region (collagen-like region, CLR) com...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more